Application of 68Ga‐ and 177Lu‐Labeled FAP Inhibitor in Evaluation and Treatment of Cardiac Fibrosis After Myocardial Infarction

Application of 68Ga‐ and 177Lu‐Labeled FAP Inhibitor in Evaluation and Treatment of Cardiac Fibrosis After Myocardial Infarction

ABSTRACT 68Ga and 177Lu‐labeled fibroblast activation protein inhibitor (FAPI) have been introduced for the diagnosis and treatment of multiple malignant and non‐malignant diseases. While several studies have examined the application of 68Ga‐FAPI in myocardial infarction (MI), research on the use of...

Full description

Saved in:
Bibliographic Details
Main Authors: Yiheng Zhao, Xiangyu Su, Boyang Xiang, Shuchen Zhang, Xiang Zhou
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:MedComm
Subjects:
cardiac fibrosis
68Ga‐FAPI
177Lu‐FAPI
myocardial infarction
Online Access:https://doi.org/10.1002/mco2.70198
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/mco2.70198

Similar Items